TY - JOUR
T1 - Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo
T2 - a Target2B! substudy
AU - van Buchem-Post, Nicoline F.
AU - Ouwerkerk, Wouter
AU - Stalman, Eileen W.
AU - van Dam, Koos P. J.
AU - Wieske, Luuk
AU - Bekkenk, Marcel W.
AU - Wolkerstorfer, Albert
AU - Spuls, Phyllis
AU - Musters, Annelie H.
AU - Bosma, Angela L.
AU - Hijnen, Dirk-Jan
AU - Eftimov, Filip
AU - Luiten, Rosalie M.
AU - T2B! immunity against SARS-CoV-2 study group
AU - van Kempen, Zoé L. E.
AU - Stalman, Eileen W.
AU - Steenhuis, Maurice
AU - Kummer, Laura Y. L.
AU - van Dam, Koos P. J.
AU - ten Brinke, Anja
AU - van Ham, S. Marieke
AU - Kuijpers, Taco
AU - Rispens, Theo
AU - Eftimov, Filip
AU - Wieske, Luuk
AU - Killestein, Joep
AU - Kooi, A. J. Vd
AU - Raaphorst, J.
AU - Zwinderman, A. H. Koos
AU - Löwenberg, M.
AU - Volkers, A. G.
AU - D'Haens, G. R. A. M.
AU - Takkenberg, R. B.
AU - Tas, S. W.
AU - Hilhorst, M. L.
AU - Vegting, Y.
AU - Bemelman, F. J.
AU - Verstegen, N. J. M.
AU - Fernandez, L.
AU - Keijzer, S.
AU - Keijser, J. B. D.
AU - Cristianawati, O.
AU - Voskuyl, A. E.
AU - Broens, B.
AU - Sanchez, A. P.
AU - Nejentsev, S.
AU - Mirfazeli, E. S.
AU - Wolbink, G. J.
AU - Boekel, L.
AU - Rutgers, B. A.
AU - de Leeuw, K.
AU - Horváth, B.
AU - Verschuuren, J. J. G. M.
AU - Ruiter, A. M.
AU - van Ouwerkerk, L.
AU - van der Woude, D.
AU - Allaart, Rcf
AU - Teng, Yko
AU - Busch, M. H.
AU - Brusse, E.
AU - van Doorn, P. A.
AU - Baars, Mae
AU - Schreurs, Crg
AU - van der Pol, W. L.
AU - Goedee, H. S.
AU - van Els, C. A. C. M.
AU - de Wit, J.
AU - Hilhorst, M.L.
N1 - Publisher Copyright:
© 2025 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
PY - 2025/4
Y1 - 2025/4
N2 - During the COVID-19 pandemic, the daily life of many patients with dermatological immune-mediated inflammatory diseases (DIMIDs), such as atopic dermatitis (AD), psoriasis, and vitiligo, was impacted by social restrictions caused by (fear of) morbidity, mortality associated with COVID-19, and vaccine hesitancy. This prospective observational, multicenter, multidisciplinary cohort study explored the impact of COVID-19 disease and vaccination on DIMIDs, specifically AD, psoriasis, and vitiligo. Data from patients with DIMIDs were collected as part of the Target2B! study (between February 2021 and October 2022). We analyzed the differences in baseline characteristics, risk of developing COVID-19, proportion of DIMIDs in patients reaching seroconversion upon vaccination per DIMID, and self-reported increase in DIMID activity by multivariable logistic regression and sensitivity analyses. A total of 424 patients with DIMID were included. COVID-19 disease commonly occurred in patients with vitiligo (51.1%), AD (42.0%), and psoriasis (34.3%) (p = 0.038). COVID-19 was not associated with the use of immunosuppressive therapy. Three patients (two with AD and one with vitiligo) were hospitalized due to COVID-19. Nearly all patients with DIMIDs exhibited effective seroconversion after regular vaccination regimens (vitiligo 100%, psoriasis 97.9%, AD 96.5%). Increased DIMID activity after COVID-19 (6.6%) or severe acute respiratory syndrome–related coronavirus (SARS-CoV-2) vaccination (12.26%) was reported in a minority of patients, with baseline progressive disease (disease activity 3 months preceding baseline survey) being the only associated risk factor (COVID-19: odds ratio [OR], 4.27 [p = 0.02]; vaccination OR, 3.45 [p = 0.002]). In conclusion, no alarming signs were shown in this study regarding (severe) COVID-19 in patients with AD, psoriasis, or vitiligo. Vaccination against COVID-19 is advised in patients with DIMIDs. Moreover, patients with DIMIDs can safely continue their immunosuppressant therapy, since this does not increase the risk of COVID-19, while vaccination-induced humoral responses are adequate. In only a minority of patients, increased DIMID activity after COVID-19 or SARS-CoV-2 vaccination occurred.
AB - During the COVID-19 pandemic, the daily life of many patients with dermatological immune-mediated inflammatory diseases (DIMIDs), such as atopic dermatitis (AD), psoriasis, and vitiligo, was impacted by social restrictions caused by (fear of) morbidity, mortality associated with COVID-19, and vaccine hesitancy. This prospective observational, multicenter, multidisciplinary cohort study explored the impact of COVID-19 disease and vaccination on DIMIDs, specifically AD, psoriasis, and vitiligo. Data from patients with DIMIDs were collected as part of the Target2B! study (between February 2021 and October 2022). We analyzed the differences in baseline characteristics, risk of developing COVID-19, proportion of DIMIDs in patients reaching seroconversion upon vaccination per DIMID, and self-reported increase in DIMID activity by multivariable logistic regression and sensitivity analyses. A total of 424 patients with DIMID were included. COVID-19 disease commonly occurred in patients with vitiligo (51.1%), AD (42.0%), and psoriasis (34.3%) (p = 0.038). COVID-19 was not associated with the use of immunosuppressive therapy. Three patients (two with AD and one with vitiligo) were hospitalized due to COVID-19. Nearly all patients with DIMIDs exhibited effective seroconversion after regular vaccination regimens (vitiligo 100%, psoriasis 97.9%, AD 96.5%). Increased DIMID activity after COVID-19 (6.6%) or severe acute respiratory syndrome–related coronavirus (SARS-CoV-2) vaccination (12.26%) was reported in a minority of patients, with baseline progressive disease (disease activity 3 months preceding baseline survey) being the only associated risk factor (COVID-19: odds ratio [OR], 4.27 [p = 0.02]; vaccination OR, 3.45 [p = 0.002]). In conclusion, no alarming signs were shown in this study regarding (severe) COVID-19 in patients with AD, psoriasis, or vitiligo. Vaccination against COVID-19 is advised in patients with DIMIDs. Moreover, patients with DIMIDs can safely continue their immunosuppressant therapy, since this does not increase the risk of COVID-19, while vaccination-induced humoral responses are adequate. In only a minority of patients, increased DIMID activity after COVID-19 or SARS-CoV-2 vaccination occurred.
KW - COVID-19
KW - atopic dermatitis
KW - psoriasis
KW - vitiligo
UR - https://www.scopus.com/pages/publications/85219175962
U2 - 10.1111/1346-8138.17664
DO - 10.1111/1346-8138.17664
M3 - Article
C2 - 39950702
SN - 0385-2407
VL - 52
SP - 624
EP - 633
JO - Journal of dermatology
JF - Journal of dermatology
IS - 4
ER -
SDG 3 Good Health and Well-being